Curaleaf Rebuts Aurora's 'Deflection' on Shareholder Value Claims

Curaleaf Escalates Rhetoric in Takeover Fight

Curaleaf accused Aurora Cannabis of deflecting from shareholder value creation in a statement issued August 25. The MSO's response came after Aurora released its own defense of management performance, a move Curaleaf characterized as sidestepping the core metric: total shareholder return over the past three years.

Curaleaf's thesis is straightforward. Aurora's stock has lagged both the North American Cannabis Operator Index and peer LPs since 2023. The company's pivot from cultivation scale to branded consumer products hasn't translated into margin expansion. That math is hard to argue with.

The statement didn't specify which Aurora filing or press release prompted the rebuttal, but the timing aligns with Aurora's Q4 2026 earnings call last week. CEO Miguel Martin emphasized international medical revenue growth and cost discipline. Curaleaf evidently sees that narrative as incomplete.

The Shareholder-Return Gap Aurora Can't Close

Aurora's three-year total shareholder return trails Curaleaf's by an estimated 47 percentage points, according to Curaleaf's investor presentation filed in July. The gap widens when adjusted for currency headwinds and dilution from Aurora's 2024 equity raise.

Key performance divergences include:

• Revenue growth: Curaleaf's U.S. retail footprint grew 18% year-over-year in Q2 2026; Aurora's medical sales grew 9%.
• EBITDA margin: Curaleaf posted 22% adjusted EBITDA margin in Q2; Aurora reported 14%.
• Cash burn: Aurora used CA$31 million in operating cash in Q4 2025; Curaleaf generated US$47 million in the same quarter.

Aurora's counter-argument has centered on its international optionality and federal-legalization upside. Curaleaf's rebuttal suggests those talking points aren't resonating with proxy advisors. ISS and Glass Lewis have yet to issue recommendations on Curaleaf's offer, which remains on the table at 0.375 Curaleaf shares per Aurora share.

What Happens Next in the Proxy Fight

The next milestone is Aurora's special shareholder meeting, tentatively scheduled for late September. Curaleaf needs 66.7% of votes cast to approve the transaction under Canadian takeover rules. That's a high bar in a contested deal.

Aurora's board has recommended shareholders reject the offer. The company has until September 10 to file a formal defense circular with the Ontario Securities Commission. Curaleaf's August 25 statement reads like a preemptive strike ahead of that filing, framing Aurora's defense as evasion rather than substance.

For more background on the Curaleaf-Aurora battle, see the CannIntel topic hub on the Curaleaf-Aurora takeover fight.

The political variable nobody can model is whether federal cannabis reform in the U.S. arrives before Aurora's shareholders vote. If Schedule III rescheduling becomes effective in Q4 2026, Curaleaf's valuation advantage narrows and Aurora's "wait-and-see" strategy gains credibility. If not, the value gap speaks for itself.